If you are interested in participating in one of our clinical trials and would like to request more information, please contact our Research Coordinator, Grace Ulerio at 212.305.6953. Please check back often as we are continuously adding new studies for which we are seeking participants.
If you are interested in possible participation in our alopecia areata studies, please complete this online FORM by providing your name, contact information and basic information regarding your hair loss. The online form must be filled out completely in order to be considered for any of the limited enrollment alopecia studies listed below. Unfortunately, we are not able to respond to direct email or phone call queries regarding participation in the studies.
Since these studies have limited enrollment, we will be unable to screen and enroll all interested and qualifying individual. However, if you indicate on the form, we will save your information and may contact you regarding future studies.
Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a medication, given as a subcutaneous injection that acts on the immune system and may reverse hair loss.
Patients diagnosed with moderate to severe alopecia areata and a current episode lasting at least 3 months in duration maybe eligible. Also patients with a history of alopecia totalis or universalis may be considered if the investigator believes that there could be possible regrowth.
All patients enrolled will receive active study medication, Abatacept. It will be self-administered by the patient as 125 mg/mL once per week, for a total of 6 months. There is no placebo group in this study. For more information .
Intralesional steroids are the most commonly used treatment for alopecia areata, yet much remains unknown about the risks and benefits of different doses of intralesional steroids. The goal of this study is to answer some of those questions.
Seeking men & women, at least 18 years old, to participate in a research study of intralesional injections of steroids versus inactive saline (salt water) for the treatment of Alopecia areata.
Those who qualify should be diagnosed with patch-type alopecia areata with 50% or less hair loss and a current episode lasting at least 3 months in duration. Patients with a history of alopecia totalis or universalis may be considered if hair loss is currently 50% or less. For more information.
The goal of this study is to test a new medication taken as a pill that acts on the immune system and may reverse hair loss.
Study participants will have monthly visits for scalp and hair examinations. A visit at week 2 for a blood draw for safety monitoring is also required. Scalp biopsies will occur at the first visit and week 12. Additional, optional scalp biopsies may be suggested at other important time points. Blood draws will occur at the first visit, week 2 and on a monthly basis during treatment and as needed to check for adverse effects or for immune studies at additional time points.
All patients enrolled will receive active study medication, Ruxolitinib. It will be given as a 20mg pill, taken twice per day, for a total of 3 months, with the possibility of extension for up to 6 months. There is no placebo group in this study. The medication may be stopped or the dose lowered if necessary in the investigator’s opinion. For more information.
The Ruxolitinib study is ongoing but is closed to further patient enrollment
National Alopecia Areata Registry
A national registry for patients with alopecia areata and their family members designed to collect information and blood samples that will help determine the genetic components and environmental factors of alopecia areata. The registry is being led by MD Anderson Cancer Center in Houston, TX, and Columbia is one of five sites participating nationally.
If you are interested in participating in this study, please register at http://www.mdanderson.org/departments/alopecia. You will be contacted by MD Anderson regarding the next step in the process.
Upcoming Alopecia Areata Studies
Tofacitinib study. Please complete form if you would like to be considered for trial.
This study is a long-term observational study of the safety of tacrolimus (Protopic®) ointment for atopic dermatitis. Participants must have been 16 years old or younger at the time of their first tacrolimus exposure and must have applied tacrolimus 0.03% or 0.1% for at least 6 weeks, continuously or intermittently. Study participants will be followed for 10 years with annual office visits. As this study does not offer an investigational treatment, participants will continue to receive standard of care as determined by their own physician.
This double-blind, randomized, vehicle-controlled chemoprevention, crossover study aims to evaluate the safety and efficacy of tazarotene 0.1% applied once daily as treatment for basal cell carcinomas in patients with basal cell nevus syndrome. Patients must be between 18 and 75 years old and must have > 3 BCCs of > 9mm sq on each of the chest and back during the year before entry into the study.
This is a double-blind, placebo-controlled, dose-escalation study of thymosin beta 4, as treatment for lesions caused by epidermolysis bullosa. Patients are randomized in a 3:1 ratio to receive either thymosin beta 4 or placebo, which will be applied topically once daily for up to 56 days. Potential participants must be at least 2 years old and have a diagnosis of junctional or dystrophic EB, confirmed by electron microscopy or immunofluorescent antigenic mapping. Additionally, patients must have at least one active, unroofed EB erosion, size 5-50cm sq., on the limb or on the trunk.
- A Prospective, Multicenter, within Subject Controlled Study to Evaluate the Effect of Apligraf® in Nonhealing Wounds of Subjects with Junctional or Dystrophic Epidermolysis Bullosa
- For each subject, two designated treatment sites of the same EB type will be selected.
- One lesion receives Apligraf® (up to 3 times over 12 weeks) and another receives Control (primary nonadherent dressing, antimicrobial dressing, nonstick gauze and standard dressing retainer).
- Rate of wound healing, recurrence of EB lesions, subject report of pain will be compared
- Patients must be ages 2 – 65
- Must have diagnosis of junctional or dystrophic epidermolysis bullosa
This prospective study is being conducted to assess the risk of complications associated with patterns of hemangiomas and to provide practitioners with guidelines for evaluating children with such lesions. We are seeking patients who fall into one of the following three groups:
- Group A - multiple hemangiomas and large cutaneous hemangiomas of infancy: incidence of hepatic hemangiomas (age < 1 year-old)
- Group B – segmental facial hemangiomas: association with PHACE syndrome (age < 1 year-old)
- Group C – lumbosacral hemangioma: association with spinal dysraphism (age < 18 years-old)
Parents will be interviewed and hemangiomas will be digitally photographed. This study is not an investigational treatment, and therefore patients will continue to receive standard of care for their hemangiomas
This randomized, third-party (observer) blinded, multi-center study compares Nitrogen Mustard 0.02% in a propylene glycol ointment (PG) vs. Nitrogen Mustard 0.02% in an Aquaphor ointment (AP) to assess the safety, tolerability, and efficacy of each as treatment for mycosis fungoides. Potential participants must have a diagnosis of stage I or IIa MF confirmed by skin biopsy and may not use steroids within 4 weeks prior to biopsy. Additionally, patients must have had prior treatment with topical therapies (PUVA, UVB, topical steroids) but no NM in the past 2 years or topical carmustine (BCNU).
Patients will receive study medication for 1 year and will then be followed for an additional year. This study requires 13 visits over 2 years (monthly at months 1-6, then months 8,10,12, then every 3 months in year two).
- Nitrogen Mustard 0.04%
- Rollover from NM 0.02% study to evaluate the efficacy, safety, and tolerability of NM 0.04% in PG ointment
- Patients may be enrolled after completing 12 months in the lower dose study if they did not achieve a complete response
- Daily application of NM 0.04% for 6 months
This international registry for pediatric CTCL aims to characterize the clinical and pathological spectrum of PEDs CTCL and gather information regarding the prognosis and the effect of the management intervention in childhood onset CTCL. Potential participants must have been under 18 years of age at the time of diagnosis, and must have either:
- biopsy proven CTCL, stage I-III, or
- biopsy suspected CTCL (atypical lymphocytic infiltrate with/without evidence of clonality), or
- biopsy proven lymphatoid papulosis, or
- biopsy proven pityriasis lichenoides chronica
The registry will capture data from local, national and international centers and send to Hospital for Sick Children in Toronto, Canada.
Despite the well-documented increased incidence of skin cancer in organ transplant recipients, multiple studies have shown that these patients are not adequately protecting themselves from the sun. The Organ Transplant Clinic within the Department of Dermatology at Columbia University Medical Center aims to implement preventive treatments to decrease future skin cancer formation; facilitate early recognition and treatment of skin cancers; and encourage teamwork between dermatologists and the transplant team in caring for patients with life threatening skin cancers.
Patients attending this clinic are invited to participate in an ongoing study that aims to assess the effectiveness of skin cancer education in OTRs and improve patient care by assessing:
- skin cancer risk factors;
- the level of pre- and post-transplant skin cancer education;
- the level of skin cancer prevention practice pre- and post-transplant;
- whether this clinic effectively educates OTRs about the incidence, risk factors, appearance, treatment and avoidance strategies for skin cancer.
Participating subjects are asked to complete a 5-page questionnaire at their first visit and a 1-page questionnaire at each follow-up visit. In order to be eligible to participate in this study, subjects must be able to sign informed consent and must be the recipient of at least one solid organ transplant.